Seek Labs Launched Infectious Disease Initiative
The company established a program to develop new therapies for 11 neglected infectious diseases.
Updated on Sept. 22, 2026 in Diseases — General
Live Poll
Should private companies prioritize research for neglected diseases over profitable drug development projects?
Seek Labs has launched the Open Impact Sequence Ablation Therapeutics Program to address diseases underserved by traditional commercial markets. This three-year initiative provides technical intelligence to research partners to accelerate therapeutic development.
Why it matters
The program aims to address a critical gap in medical research by focusing on neglected infectious diseases. It hopes to prove a new model for lowering development costs to attract more sustained global investment.
Seek Labs has mapped 145 diseases, covering 95 percent of the global infectious-disease burden, via its BioSeeker platform. The new program initially focuses on 11 neglected diseases, including Zika, rabies, and Rift Valley fever.
The players
Seek Labs
Headquartered in Salt Lake City, this biotechnology firm specializes in molecular diagnostics and therapeutic research.
Clinton Global Initiative
This organization convenes global leaders to create and implement solutions to the world's most pressing challenges.
The details
Seek Labs provides BioSeeker intelligence and therapeutic designs without upfront licensing costs to research partners. These partners then perform laboratory validation and return data to refine the Sequence Ablation Therapeutics, which currently remain investigational and lack regulatory approval.
Timeline
Seek Labs announced the program on September 22, 2026.
The initiative is scheduled to run for a duration of 3 years.
The Big Picture
This initiative follows the priorities established by the Neglected Tropical Diseases (NTD) roadmap of the World Health Organization. The program extends the global effort to combat neglected diseases by introducing a new open-access model for therapeutic design and development.
The program remains in the early research phase and does not currently offer approved treatments for human or veterinary use. Future clinical advancements from this initiative could eventually lead to new medical options for populations affected by these 11 neglected infectious diseases.
The takeaway
The program highlights an emerging trend of using open-access intelligence to bypass high commercial barriers in drug discovery. By pooling data and design instructions, the initiative aims to make research for rare or neglected diseases more economically feasible for partners.
Further reading
Learn more about the latest research and public health developments in our Diseases — General section.
Live Poll
Should private companies prioritize research for neglected diseases over profitable drug development projects?
